![]() |
Figure 4: Subject-2 has a primary cancer in the breast. The baseline RGD-K5 SUVmax measured before treatment is 1.8, and the value is 1.9 after receiving 4 doses of bevacizumab. The size measured on CT is 2.5×1.5 cm on the baseline scan, and 1.8x1.1 on the follow-up scan. The FDG uptake is much higher. The pre-treatment FDG SUVmax is 8.7, and is decreased to 2.4 after 4 doses of bevacizumab. |